Antibe Therapeutics Inc
TSX:ATE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antibe Therapeutics Inc
Other Long-Term Assets
Antibe Therapeutics Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antibe Therapeutics Inc
TSX:ATE
|
Other Long-Term Assets
CA$1.3m
|
CAGR 3-Years
63%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Long-Term Assets
$2.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
19%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other Long-Term Assets
CA$17.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other Long-Term Assets
$1.9m
|
CAGR 3-Years
114%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other Long-Term Assets
$1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Long-Term Assets
CA$35.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
28%
|
CAGR 10-Years
17%
|
|
Antibe Therapeutics Inc
Glance View
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.
See Also
What is Antibe Therapeutics Inc's Other Long-Term Assets?
Other Long-Term Assets
1.3m
CAD
Based on the financial report for Sep 30, 2023, Antibe Therapeutics Inc's Other Long-Term Assets amounts to 1.3m CAD.
What is Antibe Therapeutics Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
34%
Over the last year, the Other Long-Term Assets growth was 0%. The average annual Other Long-Term Assets growth rates for Antibe Therapeutics Inc have been 63% over the past three years , 34% over the past five years .
